Novartis Revises Zelnorm Labeling With Diarrhea, Ischemic Colitis Risk Info
Executive Summary
Novartis has revised labeling for the irritable bowel syndrome therapy Zelnorm to include the risk of developing severe diarrhea and ischemic colitis, FDA says in a 1"Talk Paper" issued April 28
You may also be interested in...
Market Snapshot: Taking Constipation Seriously – Linaclotide Success Raises Hopes For Market Resurgence
The constipation and irritable bowel syndrome markets have sucked up some prescription drug contenders like quicksand. But the Phase III success of Ironwood Pharmaceuticals' linaclotide is renewing hope that an underserved and arguably under-appreciated market could blossom, despite regulatory and commercial challenges that have hindered candidates in the past.
Market Snapshot: Taking Constipation Seriously – Linaclotide Success Raises Hopes For Market Resurgence
The constipation and irritable bowel syndrome markets have sucked up some prescription drug contenders like quicksand. But the Phase III success of Ironwood Pharmaceuticals' linaclotide is renewing hope that an underserved and arguably under-appreciated market could blossom, despite regulatory and commercial challenges that have hindered candidates in the past.
Taking Constipation Seriously: Linaclotide Success Raises Hopes For Market Resurgence
The constipation and irritable bowel syndrome markets have sucked up some prescription drug contenders like quicksand. But the Phase IIII success of Ironwood Pharmaceuticals' linaclotide is renewing hope that an underserved and arguably under-appreciated market could blossom, despite regulatory and commercial challenges that have hindered candidates in the past.